A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
FA Büttner, S Winter, V Stühler, S Rausch… - Genome Medicine, 2022 - Springer
Background Renal cell carcinoma (RCC) is a heterogeneous disease comprising
histologically defined subtypes. For therapy selection, precise subtype identification and …
histologically defined subtypes. For therapy selection, precise subtype identification and …
[HTML][HTML] G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3
Q Zhang, Z Yang, Q Han, H Bai, Y Wang, X Yi, Z Yi… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Ectopic Glucose 6-phosphate dehydrogenase (G6PD) expression plays important role in
tumor cell metabolic reprogramming and results in poor prognosis of multiple malignancies …
tumor cell metabolic reprogramming and results in poor prognosis of multiple malignancies …
Co-regulation of immune checkpoint PD-L1 with interferon-gamma signaling is associated with a survival benefit in renal cell cancer
J Hänze, M Wegner, E Noessner, R Hofmann… - Targeted Oncology, 2020 - Springer
Background Programmed death ligand (PD-L1)-based immune checkpoint blockade
therapy for metastatic renal cell carcinoma (RCC) achieves significant response rates in a …
therapy for metastatic renal cell carcinoma (RCC) achieves significant response rates in a …
NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC
Q Zhang, Z Yang, Y Ni, H Bai, Q Han, Z Yi, X Yi… - Cancer cell …, 2020 - Springer
Background Glucose 6-phosphate dehydrogenase (G6PD) serves key roles in cancer cell
metabolic reprogramming, and has been reported to be involved in certain carcinogenesis …
metabolic reprogramming, and has been reported to be involved in certain carcinogenesis …
[HTML][HTML] Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma
O Ichiyanagi, H Ito, S Naito, T Kabasawa, H Kanno… - Oncotarget, 2019 - ncbi.nlm.nih.gov
Background: We investigated the roles of eIF4E phosphorylation (Ser209) in tumour
recurrence after curative nephrectomy for localized clear cell renal cell carcinoma (ccRCC) …
recurrence after curative nephrectomy for localized clear cell renal cell carcinoma (ccRCC) …
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer
H Jörg, M Wegner, N Elfriede, R Hofmann… - Targeted …, 2020 - search.proquest.com
Background Programmed death ligand (PD-L1)-based immune checkpoint blockade
therapy for metastatic renal cell carcinoma (RCC) achieves significant response rates in a …
therapy for metastatic renal cell carcinoma (RCC) achieves significant response rates in a …